Back to search
Wet Age-related Macular Degeneration (wAMD)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration (wAMD) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration (wAMD) trials you may qualify forThis is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-…
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (…
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will eval…
This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up…
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-…
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-re…